🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Spain / NCT07494110
Recruiting Not applicable

Aurora: AI-Based Narrative Intervention to Support Emotional Well-Being in Clinical and Non-Clinical Populations

NCT07494110 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-02-12
Last updated
2026-03-27

Condition(s) studied

InstitutionalizationElderlyMental HealthWellbeingAging

Investigational drug(s) / intervention(s)

chatbot-mediated supportive care intervention

chatbot-mediated supportive care intervention: Aurora is a guided narrative reconstruction chatbot combining structured storytelling and reminiscence with an AI-based conversational system and support from a trained facilitator. Participants co-create a personalized life narrative ("life book") with written content and optional audio contributions (with explicit consent). Sessions occur in a secure professional environment and are supervised by licensed mental health professionals to ensure emotional safety. Aurora is not a diagnostic tool and is intended to promote emotional expression, recovery-oriented processes, and emotional well-being. The intervention is delivered in structured guided sessions. Arm 1 receives a single-session version for refinement and usability assessment, whereas Arms 2 and 3 receive a 4-hour intervention delivered over two weeks. The total intervention dose is equivalent across Arms 2 and 3. Session structure differs to accommodate participant characteristics.

Study summary

Aurora is an interdisciplinary project evaluating a chatbot-mediated supportive care intervention designed to promote emotional expression, autobiographical meaning-making, identity processes, and emotional well-being through guided narrative reconstruction. The Aurora system provides a structured, person-centered storytelling process supported by generative AI and human facilitation. Under the supervision of a trained facilitator (licensed mental health professional), participants engage in guided reminiscence and storytelling sessions to co-create a personalized "life book." The chatbot is not a diagnostic or treatment tool; rather, it is intended to support emotional expression, narrative reconstruction, and recovery-oriented processes. The study includes three non-randomized arms implemented sequentially: (1) a single-session arm of healthy adults focused on acceptability, usability, and emotional safety; (2) a four-hour intervention arm of adults with DSM-5 diagnosed mental disorders in residential care; and (3) a four-hour intervention arm of healthy older adults aged 65 years and older. Quantitative outcomes assess affect, mental well-being, and recovery-related constructs. Additional measures include usability, satisfaction, and qualitative feedback. Ecological momentary assessment (EMA) is conducted in Arms 2 and 3.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria Arm 1: Healthy Adults (Single-Session Intervention) Age 18 years or older at screening. Sufficient ability to read and understand Spanish to follow study instructions and complete questionnaires. Ability to engage in a brief guided interaction and complete self-report measures. Able and willing to provide written informed consent. \--- Arm 2: Adults with DSM-5 Diagnosed Mental Disorder in Residential Care (4-hour Intervention) Age 18 years or older at screening. Currently residing in a participating long-term mental health residential care facility and expected to remain there for the duration of the intervention and post-assessment period. Documented diagnosis of a mental disorder according to DSM-5 criteria, confirmed by the treating clinician. Minimal clinical stability at baseline, defined as all of the following: Clinically stable in the judgment of the treating clinician. No requirement for acute psychiatric hospitalization or crisis intervention in the previous 4 weeks. Clinical Global Impression - Improvement (CGI-I) score between 3 and 5 inclusive during the 4 weeks prior to enrollment, indicating relative clinical stability. Sufficient ability to understand spoken and written Spanish to participate in study procedures. Ability to engage in guided interaction and provide feedback. Able and willing to provide informed consent; when applicable, provision of legal guardian consent plus participant assent. Willingness to participate in all study procedures. \--- Arm 3: Healthy Older Adults (≥65 Years; 4-hour Intervention) Age 65 years or older at screening. No self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder). Sufficient ability to read and understand Spanish to participate in study procedures. Adequate cognitive and communication abilities to engage in guided interaction and complete questionnaires. Able and willing to provide written informed consent. \--- Exclusion Criteria Arm 1: Healthy Adults Current acute medical or psychiatric condition that would compromise safe participation or data validity. Moderate or high acute suicide or self-harm risk at screening. Significant cognitive, communication, or comprehension impairment that would interfere with participation. Explicit refusal to participate. \--- Arm 2: Adults with DSM-5 Diagnosed Mental Disorder in Residential Care Current acute psychiatric decompensation requiring crisis-level care. Moderate or high acute suicide or self-harm risk at screening or baseline. High risk of clinically significant emotional harm from autobiographical life review, defined as treating clinician judgment that narrative or reminiscence work is contraindicated due to one or more of the following: Severe clinical destabilization within the past 3 months. Trauma-related re-experiencing symptoms. Marked dissociative symptoms. Inability to provide informed consent, with no legal representative available when required, or lack of participant assent when applicable. Significant cognitive, communication, or comprehension impairment without available supports. Explicit refusal to participate. Imminent discharge or transfer that would prevent completion of the intervention or post-assessment. \--- Arm 3: Healthy Older Adults Self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder). Moderate or high acute suicide or self-harm risk at screening. Current acute medical or psychiatric condition that would compromise safe participation. Significant cognitive, communication, or comprehension impairment that would interfere with participation. Explicit refusal to participate.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Llar Residència Gràcia(Grup ATRA) Barcelona Barcelona Not Yet Recruiting
Department of Clinical and Health Psychology; Universitat Autònoma de Barcelona Cerdanyola del Vallès Barcelona Recruiting

More Universitat Autonoma de Barcelona trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07494110 on ClinicalTrials.gov ↗ ← All trials in Spain